Welcome to our dedicated page for Cytomx Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on Cytomx Therapeutics stock.
CytomX Therapeutics develops oncology biologics built on its PROBODY therapeutic platform, which masks and conditionally activates antibody-based therapies in the tumor microenvironment. News about CTMX commonly covers clinical updates for varsetatug masetecan, or Varseta-M, an EpCAM PROBODY ADC studied in advanced colorectal cancer and other EpCAM-expressing tumors, as well as CX-801, a masked Interferon-alpha-2b program initially developed in advanced melanoma.
Company updates also address financial results, research and development spending, cash runway, equity financings, and collaboration activity with Amgen, Regeneron, and Moderna. Recurring pipeline coverage includes dose-expansion data, combination-study activity, regulatory interactions, and PROBODY platform applications such as bispecific immunotherapies and T-cell engagers.
CytomX Therapeutics (NASDAQ:CTMX) has announced the pricing of an underwritten public offering of 76,923,076 shares of common stock at $1.30 per share, aiming to raise approximately $100 million in gross proceeds. The offering, expected to close on May 13, 2025, features participation from notable investors including Longitude Capital, OrbiMed, Venrock Healthcare Capital Partners, Vivo Capital, and RTW Investments.
The company plans to use the proceeds for research and development, general corporate purposes, and working capital needs. Jefferies and Piper Sandler are serving as joint book-running managers for the offering, which is being conducted through an effective shelf registration statement filed with the SEC.
CytomX Therapeutics (NASDAQ: CTMX), a company specializing in masked, conditionally activated biologics, has scheduled its first quarter 2025 financial results announcement for Monday, May 12, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT following the announcement.
Interested participants can access the live webcast through CytomX's investor relations website and are advised to register for the conference call at least 10 minutes before it begins. A replay of the webcast will be made available on the company's website after the event.
CytomX Therapeutics and Moderna have unveiled promising preclinical data for their collaborative development of an mRNA-encoded masked IL-12 molecule at the AACR Annual Meeting in Chicago.
The breakthrough combines CytomX's PROBODY® masking technology with Moderna's mRNA expertise to create a novel cancer treatment approach. The key innovation lies in developing an IL-12 therapeutic that can be selectively activated within the tumor microenvironment while minimizing systemic activity.
Key highlights:
- Successfully demonstrated proof of concept for mRNA encoded masked molecule in cancer treatment
- Achieved enhanced tolerability while maintaining anti-tumor efficacy
- Addresses previous limitations of IL-12's clinical use due to inflammatory toxicity
The research findings will be presented in Poster #3127/12 on April 28, 2025, highlighting how this innovative combination of technologies could potentially overcome traditional IL-12 therapy limitations.
CytomX Therapeutics (CTMX) reported its 2024 financial results, highlighting progress in its clinical pipeline. The company's lead program, CX-2051, a PROBODY Topo-1 ADC targeting EpCAM in advanced colorectal cancer, is advancing with initial Phase 1a data expected in 1H 2025. The Phase 1 study is currently at the seventh dose level.
Financial highlights include total revenue of $138.1 million for 2024, up from $101.2 million in 2023, driven by research program collaborations. The company ended 2024 with $100.6 million in cash and investments. Operating expenses increased to $113.1 million from $107.7 million, primarily due to a $5.0 million milestone payment to AbbVie.
In January 2025, CytomX announced a 40% workforce reduction to focus resources on CX-2051. The company's cash runway extends into Q2 2026. A new $5 million milestone payment was triggered in February 2025 from the Astellas collaboration.
CytomX Therapeutics (Nasdaq: CTMX), a pioneer in masked, conditionally activated biologics, has announced its participation in the upcoming Barclays 27th Annual Global Healthcare Conference.
The company's CEO and chairman, Sean McCarthy, D.Phil., is scheduled to deliver a presentation on Wednesday, March 12, 2025, at 3:00 p.m. ET. Investors and interested parties can access a live webcast of the presentation through the Events and Presentations section of CytomX's website at www.cytomx.com.
Additionally, the management team will be available for one-on-one meetings with registered conference attendees.
CytomX Therapeutics (Nasdaq: CTMX), a company specializing in masked, conditionally activated biologic therapeutics, has scheduled the release of its fourth quarter and full year 2024 financial results for March 6, 2025, after U.S. markets close.
The company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT on the same day. Interested participants can access the webcast through CytomX's investor relations website and are advised to register at least 10 minutes before the call begins.
CytomX Therapeutics (Nasdaq: CTMX), a pioneering company in masked, conditionally activated biologics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Sean McCarthy, D.Phil., the company's CEO and chairman, is scheduled to deliver a presentation on Wednesday, January 15, 2025, at 1:30 p.m. PT.
The presentation will be accessible through a live webcast on the Events and Presentations section of CytomX's website. Additionally, the management team will be available for individual meetings with registered conference investors.